Urinary kidney stone inhibitors. What is the news?
Urinary kidney stone inhibitors. What is the news?
复制标题
DOI：
10.1159/000030214
复制
发表时间：
1998-01-01
影响因子：
1.6
通讯作者：
Berland, Y
中科院分区：
文献类型：
--
作者：
Dussol, B;Berland, Y
相对于钙盐（草酸盐和磷酸盐）的过饱和是导致结晶和肾结石的驱动力。高分子量尿抑制剂是最近描述的能够改变肾结石形成过程的分子。通过抑制晶体成核、生长和聚集以及通过抑制晶体与肾小管细胞的相互作用，这些蛋白质有效地防止结石形成和保留在尿路中。但是，尽管付出了相当大的努力，这些蛋白质的表征仍在进行中。除了钙盐过饱和危险因素的病理生理学，如特发性高钙尿症或高钙尿症，蛋白质抑制剂的肾脏参与是肾结石综合治疗中最令人兴奋的领域，肾结石是一种影响西方国家高达10%的人的疾病。
Supersaturation with respect to calcium salts (oxalate and phosphate) is the driving force leading to crystalluria and nephrolithiasis. High-molecular-weight urinary inhibitors are recently described molecules capable of altering the process of kidney stone formation. By inhibition of crystal nucleation, growth and aggregation and by inhibition of crystal interaction with tubular cells, these proteins efficiently prevent stone formation and retention in the urinary tract. But in spite of considerable efforts, characterization of these proteins is still under way. Besides the pathophysiology of risk factors for calcium salts supersaturation such as idiopathic hypercalciuria or hyperoxaluria, the renal involvement of protein inhibitors is the most exciting field in the comprehensive approach of nephrolithiasis, a disease that affects up to 10% of people in Western countries.